微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 24.11% | -9.57% | -7.23% | 128/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 25.98% | -8% | -0.15% | 126/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 26.02% | -7.8% | -3.77% | 124/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 27.04% | -7.5% | 1.45% | 123/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 26.66% | -6.15% | -5.62% | 119/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 28.24% | 7.74% | 0.06% | 122/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 28.23% | 11.66% | -3.46% | 119/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 29.24% | 17.94% | 2.93% | 119/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 28.4% | 13.33% | 8.36% | 120/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 26.21% | 6.28% | 3.69% | 126/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 25.28% | 10.62% | 1.98% | 128/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 24.79% | 5.82% | -1.1% | 128/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 25.06% | 5.53% | 1.62% | 125/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 24.67% | 4.01% | 7.93% | 131/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 22.85% | -2.44% | -2.45% | 129/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 23.43% | 1.42% | -1.37% | 134/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 23.75% | 3.71% | 0.16% | 126/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 23.71% | 8.99% | 1.24% | 135/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 23.42% | 10.97% | 1.4% | 123/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 23.1% | 7.88% | 0.86% | 131/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 22.9% | 27.29% | 5.26% | 115/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 21.76% | -9.1% | 3.08% | 135/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 21.11% | -8.78% | -1.42% | 112/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 21.41% | -8.88% | 19.01% | 121/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 17.99% | -16.85% | -24.83% | 103/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 23.94% | -12.12% | 3.44% | 124/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 23.14% | -11.1% | -1.52% | 99/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 23.5% | -15.79% | 8.6% | 106/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 21.64% | -24.47% | -20.56% | 98/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 27.24% | 5.24% | 4.64% | 119/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 26.03% | 4% | -6.72% | 93/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 27.91% | 5.86% | -2.59% | 93/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 28.65% | 23.24% | 10.69% | 87/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 25.88% | -2.11% | 3.41% | 111/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 25.03% | -2.05% | -5.05% | 87/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 26.36% | 5.37% | 13.4% | 87/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 23.25% | 1.74% | -12.08% | 79/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 26.44% | 6.06% | 3.47% | 96/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 25.55% | 2.9% | 2.14% | 68/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 25.02% | 0.69% | 9.5% | 78/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 22.85% | -7.66% | -8.35% | 68/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |